Clinical Trials Logo

Clinical Trial Summary

This study is a clinical study to investigate the gluconeogenesis pathway related to visceral adipose tissue (VAT) in obese individuals without type 2 diabetes and the effects of empagliflozin (EMPA) on glucose homeostasis in viscerally-obese individuals using functional studies of glycerol metabolism in hepatic gluconeogenesis using a well-validated nuclear magnetic resonance (NMR) spectroscopy platform.


Clinical Trial Description

Diabetes mellitus type II is the consequence of insulin resistance and pancreatic beta cell failure resulting from a variety of metabolic insults, one of which is excess body adiposity/obesity. In the diabetic individual, hepatic gluconeogenesis may go uninhibited due to failure of the body's normal feedback mechanisms to appropriately incorporate glucose into cells via insulin signaling, leading to excess gluconeogenesis and hyperglycemia. The substrate for this excess glucose derives from multiple sources in the liver including dietary glycerol, adipose-derived glycerol from lipolysis, and substrates from the citric acid cycle. In the normal state, lipolysis is maintained at a steady state in equilibrium between stored dietary triglycerides and free fatty acids. However, in situations of triglyceride excess (e.g. in the obese state), lipolysis may become overactive resulting in increased free fatty acids and adipose-derived glycerol. This excess glycerol drives hepatic gluconeogenesis and is incorporated into glucose and released into the blood, leading to hyperglycemia, and ultimately diabetes and its clinical sequelae.

A popular hypothesis linking visceral fat with excess gluconeogenesis is delivery of glycerol arising from mesenteric triglyceride turnover directly into the portal circulation and to the liver. Glycerol is a primary substrate for gluconeogenesis in the liver. Under normal conditions, hepatic gluconeogenesis begins from glycerol ingested in the diet which is converted to glycerol-3-phosphate and subsequently dihydroxyacetone phosphate (DHAP) in the liver. DHAP is converted to fructose-1,6-bisphosphate which undergoes a series of reactions to become a single 6-carbon glucose molecule. Adipocytes contribute glycerol to hepatic gluconeogenesis through lipolysis of triglyceride stores. Although glycerol-gluconeogenesis has been extensively studied in animals, the traditional reliance on radioactive tracers makes translation to humans difficult for many reasons. We aim to use new techniques to explore the mechanisms behind altered glucose metabolism related to excess visceral adiposity in obese adults by quantifying the relative contributions of varying substrates to liver-derived glucose. One such method uses 13C3 labeled glycerol to trace the incorporation of glycerol from dietary sources to hepatic gluconeogenesis. This technology utilizes nuclear magnetic resonance (NMR) spectroscopy, a technique that does not require ionizing radiation and has been extensively validated, to analyze the NMR spectra of plasma glucose and quantify the "percent enrichment" of the circulating glucose molecules with labeled glycerol. In turn, differences in enrichment reflect variability in hepatic glucose metabolism as it relates to the contribution of glycerol from visceral adipose tissue to gluconeogenesis.

The rationale of this project is to utilize existing technology to investigate the impact of excess visceral adiposity on glycerol metabolism in hepatic gluconeogenesis in obese adults without diabetes and to explore the effects of treatment with EMPA on visceral adiposity related glucose homeostasis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02833415
Study type Interventional
Source University of Texas Southwestern Medical Center
Contact
Status Completed
Phase Phase 4
Start date March 2016
Completion date November 2018

See also
  Status Clinical Trial Phase
Completed NCT04807959 - Evaluation of the Effectiveness of a Comprehensive Visceral Adiposity-Focused Anti-Obesity Program
Completed NCT06377358 - Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy. N/A
Completed NCT04754464 - Clinical Study on the Effect of a Synbiotic on Body Fat Mass N/A
Not yet recruiting NCT04942093 - NUTritional Impact of a Hypocaloric Hyperprotein Diet Before Obesity Surgery N/A
Completed NCT03239782 - The "Metabolically-obese Normal-weight" Phenotype and Its Reversal by Calorie Restriction N/A
Completed NCT06158191 - Long-term Benefits of Abdominal Fat Loss in Abdominally Obese Dyslipidemic Patients (SYNERGIE Study) N/A
Recruiting NCT04100616 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Obesity
Completed NCT04780828 - Investigation of the Effects of Different Levels of Obesity on the Respiratory System
Completed NCT05895916 - Extreme Exercise and Energy Expenditure (4E) Study N/A
Completed NCT04436419 - Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study N/A
Completed NCT03038620 - Impact of Liraglutide 3.0 on Body Fat Distribution Phase 4
Completed NCT04255173 - Anthropometric And Body Composition Measurements Related To Osteoporosis In Geriatric Population N/A
Completed NCT04592107 - The Association of Visceral Adiposity Index With Progression of Chronic Kidney Disease
Completed NCT03542864 - Medical Supervised Duodenal-Enteral Feeding Treatment N/A
Completed NCT05789888 - Genes Variability in Obesity and Normal Body Weight Patients.